Phase II clinical trials of WT1 vaccine for post hematopoietic stem cell transplant patients

Phase II clinical trials of WT1 vaccine for post hematopoietic stem cell transplant patients - Phase II clinical trials of WT1 vaccine for post hematopoietic stem cell transplant patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011780

Enrollment

Registered

2013-09-19

Start date

2012-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia

Interventions

WT1 peptide vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AML or ALL post HSCt high risk for relapse (HSCT in non-CR, 2nd HSCT for relapse)

Exclusion criteria

Exclusion criteria: Double cancer Infectious disease Heart failure

Design outcomes

Primary

Measure	Time frame
2year OS PFS	—

Countries

Japan

Contacts

Public ContactNaoki Hosen

Osaka University Graduate School of Medicine Medicine

hnaoki@imed3.med.osaka-u.ac.jp0668793676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026